干白素-23抑制剂降低了银病患者的纤维化-4指数,但干白素-17抑制剂并没有降低纤维化-4指数
Ryosuke Takeshima1, Masahiro Kamata1, Shoya Suzuki1
1Department of Dermatology, Teikyo University School of Medicine, Tokyo, Japan.
The Journal of dermatology
|May 28, 2024
概括
纤维化-4 (FIB-4) 指数与牛皮患者的年龄相关. 干白素-23 (IL-23) 抑制剂,但不是IL-17 抑制剂,在基线得分升高的患者中降低了FIB-4 评分.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 皮肤病学 皮肤病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 牛皮与肝脏疾病有关.
- 纤维化-4指数 (FIB-4) 是评估肝纤维化的非侵入性工具.
- 关于牛皮的FIB-4指数和生物药物的影响的数据有限.
研究的目的:
- 调查FIB-4指数与牛皮患者特征之间的关系.
- 评估生物疗法,特别是IL-17和IL-23抑制剂对牛皮患者FIB-4指数的影响.
主要方法:
- 对171名牛皮患者 (36-64岁) 的回顾性分析,这些患者接受了IL-17或IL-23抑制剂的治疗.
- FIB-4指数与人口/临床因素之间的相关性分析.
- 生物治疗6个月前和后FIB-4指数得分的比较.
主要成果:
- 在以前没有使用过生物药物的患者中,FIB-4指数和年龄之间发现了微弱的正相关性.
- 总体而言,没有观察到任何生物药物对FIB-4指数的显著变化.
- 与IL-17抑制剂不同的是,IL-23抑制剂在6个月内显著降低了FIB-4指数得分,这些患者的基线得分较高 (>1.3),与IL-17抑制剂不同.
结论:
- FIB-4指数显示了牛皮患者与年龄的相关性.
- IL-23抑制剂可以改善牛皮患者的肝纤维化标志物,这些患者基线FIB-4得分升高.
- 需要进一步的研究来证实IL-23抑制剂对肝纤维化的功能影响.
相关概念视频
T Cell Types and Functions
1.0K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.0K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
131
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
131
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
158
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
158
Inflammatory Bowel Disease IV: Pharmacological Management
126
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
126
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
115
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
115
Drugs Used in Lower Respiratory Disorders: Overview
421
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
421


